costa_na 发表于 2014-7-15 11:18:41

草船借箭 发表于 2014-7-15 10:04
http://www.18222788817.com/kangairiji/2013/24.html
易瑞沙如何减量服用?



The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.

Abstract:

Background: NEJ002, a phase III trial comparing gefitinib with carboplatin-paclitaxel as the first-line treatment for advanced NSCLC with sensitive EGFR mutations, showed a significant improvement in progression-free survival (PFS) in the gefitinib arm. Although standard schedule of gefitinib was the administration of 250 mg tablet every day, more than half of patients in the gefitinib arm reduced the dose of gefitinib mainly because of toxicities. However, the efficacy of such low-dose (LD) gefitinib has rarely been evaluated.

Methods: A post-hoc analysis of the efficacy (response rate and survival) in patients who took gefitinib without any dose reduction during their treatment period and those in patients who received LD gefitinib at any point during the treatment period was performed.

Results: Among 114 patients of the first-line gefitinib group in NEJ002, 52 (46%) continued gefitinib without break until their diseases progressed (categorize as group A), and 62 (54%) was reduced their dose of gefitinib (most of them moved into every-2-days schedule) because of some toxicities (same as group B). There was no significant difference of patient characteristics between two groups. Interestingly, PFS of group B seemed to be better than that of group A (median PFS, 301 days in group A versus 351 days in group B; p = 0.450) and overall survival was also similar between the groups (median survival time, 852 days versus 928 days, respectively; p = 0.674).
62名患者减量服用吉非替尼(大多数换成了两天一片的用药方案)

Conclusions: The results suggest that LD gefitinib may be clinically not inferior to standard schedule of gefitinib for NSCLC with sensitive EGFR mutations. Considering the merit in terms of risk-benefit balance, prospective study of LD gefitinib is warranted.

http://meetinglibrary.asco.org/content/43760-74

草船借箭 发表于 2014-7-16 13:08:04

草船借箭 发表于 2014-7-17 13:31:20

http://mp.weixin.qq.com/s?__biz=MjM5Nzc4MDk2MA==&mid=200886198&idx=1&sn=bf79c26411821971fee8e74f1919dd7a#rd
【407】【ASCO之海内外专家新视点】Thomas James Lynch & 李峻岭 教授

草船借箭 发表于 2014-7-18 14:06:32

本帖最后由 草船借箭 于 2014-7-18 14:11 编辑

http://wenku.baidu.com/view/94be8dfd04a1b0717fd5dd53.html
http://wenku.baidu.com/view/e748015d804d2b160b4ec066.html

1480003056 发表于 2014-7-19 17:36:50

草船你好!我妈妈吃9291(60)毫克的第一个月CEA55.24降到51.99,第二个月9291(70)毫克51.99升到61.12,难道这么快耐药了?现在9291(60)毫克联184(40)毫克,已经吃了3天了,我妈妈好像没什么副反应,要是9291联184效果也不好,下一步该吃什么药好呢?谢谢帮忙分析一下!http://www.yuaigongwu.com/forum.php?mod=viewthread&tid=13997&extra=

草船借箭 发表于 2014-7-20 07:11:15

本帖最后由 草船借箭 于 2014-9-9 20:54 编辑

发热是恶性肿瘤中晚期阶段常见的症状。
恶性肿瘤引起发热有多种原因。
比如:癌组织生长过速,血液供应不足,引起坏死、液化和溃烂,这些坏死的癌组织被人体吸收,要引起发热;
在癌组织刺激下,机体发生白细胞向肿瘤组织浸润等免疫反应,白细胞释放出的致热原也引起发热;
癌灶及周围组织合并细胞感染,或者癌组织阻塞空腔器官,使之引流不畅而继发局部或全身性感染引起感染性发热;
使用某些抗癌药物,有发热的不良反应;
以及癌症病人长期营养不良、过度消耗,致使体温调节中枢失去平衡等等,都会引起发热。

治疗发热,要了解引起发热的原因
如果因为继发感染,应该先抗感染,控制感染体温就会下降。因体温调节中枢失去平衡或其他原因不明的发热,需对症治疗外。   
(—)抗感染退热   恶性肿瘤的继发感染,要根据抗菌谱和药物敏感试验选用抗菌药物。选用时还应注意病人的肝肾功能情况,有肝、肾功能不全的,不用损伤肝、肾功能的药。使用剂鲎要足,不滥用维持置。开始时尽量不用广谱抗生素。总之,避免产生耐药性,及时、有效地控制感染。  

 (二)发热的对症处理   
(1)物理降温:体温达39C以上,可以采用物理降温。
①用50%乙醇擦浴、擦背部、胸部和四肢。
②用冷水、冰块、冰袋置于大血管、前额处。   
(2)化学药物退热:
①吲哚美辛:25mg 1片,每次1片,每日3次。或用吲哚美辛栓剂塞肛,每日2次。
②阿司匹林:0.3g1片,每次1~2片,每日3次。③安乃近:0。5g1片,每次1片,每日3次。
④复方氨基比林针剂:1~2rn1 1次,肌肉注射。 ⑤对乙酰胺基酚:0.3g1片,每次1片,1日3次。   
(3)糖皮质激素退热:使用以上治疗后,效果仍不好时,可以用皮质激素类药。但是有感染必须与抗生素一起用,有严重感染中毒症状者慎用。常用的有:①泼尼松龙片剂:5~10mg1次,每日3~4次,或青用注射剂,10~20mg,加入葡萄糖溶液、生理盐水中静滴。
②氢化可的松片:20mgl次,每日2~3次,注射剂100~200mg 1天,静滴。
③地塞米松:0.75~1.5mgl次,每日2~3次,或注射剂4~20mg1次,静滴。④氢化可的松:100~200mg稀释后静滴。

草船借箭 发表于 2014-7-21 16:19:15

http://item.taobao.com/item.htm?spm=a230r.1.14.40.uiucvt&id=35332234975&ns=1#detail

http://item.taobao.com/item.htm?spm=2013.1.0.0.n6E1xF&scm=1007.10009.518.0&id=14247885248&pvid=9e986f62-7036-4c07-8087-26ba621b6791&qq-pf-to=pcqq.c2c

http://item.taobao.com/item.htm?spm=a230r.1.14.51.04W18U&id=14600227734&ns=1#detail&qq-pf-to=pcqq.c2c

草船借箭 发表于 2014-7-21 16:26:53

http://gnc.tmall.com/?spm=a1z10.1.w5001-7657282158.3.9Iq9eg&scene=taobao_shop

1480003056 发表于 2014-7-21 19:16:08

草船你好!我妈妈吃9291(60)毫克的第一个月CEA55.24降到51.99,第二个月9291(70)毫克51.99升到61.12,难道这么快耐药了?现在9291(60)毫克联184(40)毫克,已经吃了5天了,我妈妈好像没什么副反应,要是9291联184效果也不好,下一步该吃什么药好呢?谢谢帮忙分析一下!http://www.yuaigongwu.com/forum. ... id=13997&extra=

草船借箭 发表于 2014-7-23 13:06:52

http://mp.weixin.qq.com/s?__biz=MjM5Nzc4MDk2MA==&mid=200785223&idx=4&sn=c7958e63f3722177f61e68ac5d350670&key=540a4984c4f01b4d3cb8d86d7259cfe33160bad8aab2107d0e7a62dce433908b2ff8efd3f780895ee4124a9e2d71b6c9&ascene=7&uin=MjI3NjM1NzEwNQ%3D%3D综述:氧疗在晚期肺癌患者中的应用
页: 36 37 38 39 40 41 42 43 44 45 [46] 47 48 49 50 51 52 53 54 55
查看完整版本: 八十岁母亲肺腺癌,抗癌六年